Two randomised, phase III studies to evaluate the benefits of anti-HER2 therapy combined with perioperative chemotherapy in gastric or locally advanced GEJ adenocarcinoma are underway, INNOVATION and PETRARCA. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.